Arax Advisory Partners
HZNP

Arax Advisory Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Arax Advisory Partners’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-89
Closed -$10.3K – 1456
2023
Q3 		$10.3K Buy
89
+30
+51% +$3.22K ﹤0.01% 713
2023
Q2 		$6.07K Buy
59
+14
+31% +$1.48K ﹤0.01% 821
2023
Q1 		$4.91K Sell
45
-2
-4% -$221 ﹤0.01% 853
2022
Q4 		$5.35K Buy
47
+31
+194% +$2.58K ﹤0.01% 782
2022
Q3 		$1K Sell
16
-9
-36% -$629 ﹤0.01% 1204
2022
Q2 		$2K Sell
25
-21
-46% -$1.99K ﹤0.01% 992
2022
Q1 		$5K Buy
46
+39
+557% +$3.8K ﹤0.01% 807
2021
Q4 		$1K Hold
7
– – ﹤0.01% 1134
2021
Q3 		$1K Buy
+7
New +$727 ﹤0.01% 982

Other funds holding HZNP

IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Blue Trust Inc
Blue Trust Inc Alpharetta, Georgia $9.51B AUM 13.02% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.22B AUM 22.8% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
Huntington National Bank
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Arax Advisory Partners's HZNP Position: Q4 2023 in Review

Arax Advisory Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 89 shares — an estimated $10.3K sold.

Arax Advisory Partners first reported a position in HZNP in Q3 2021 and held it in 9 quarters. The position peaked at $10.3K in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Arax Advisory Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Arax Advisory Partners sold 89 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $10.3K.
  • Arax Advisory Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2021 and held it in 9 quarters.
  • Arax Advisory Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $10.3K in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Arax Advisory Partners's 13F filing for Q4 2023, filed 6 Feb 2024.